cangrelor

Ligand id: 1776

Name: cangrelor

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: cangrelor

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 17
Hydrogen bond donors 7
Rotatable bonds 16
Topological polar surface area 335.94
Molecular weight 774.95
XLogP -0.92
No. Lipinski's rules broken 3

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In June 2015, cangrelor was apprioved as an adjunct which may be used to prevent the formation of harmful blood clots in the coronary arteries in patients undergoing percutaneous coronary intervention.
Mechanism Of Action and Pharmacodynamic Effects
Cangrelor is a P2Y12 inhibitor [6]. Inhibition of P2Y12 reduces ADP-mediated platelet activation and aggregation. This compound has a more rapid onset and reversal of action than currently approved antiplatelet drugs [2], making it a potentially effective bridging therapy in patients requiring surgical intervention.